[Cellular kinetics and outcome of tisagenlecleucel for diffuse large B-cell lymphoma].

Abstract

CD19-targeted chimeric antigen receptor T-cell (CAR-T) therapy has shown promise as treatment of relapsed or refractory B-cell malignancies. However, the clinical utility of early CAR-T monitoring within 1 month after infusion has not been elucidated. In this study, we quantitatively measured CAR-T kinetics in peripheral blood on days 2, 4, 7, 9, 11, 14, 21, and 28 post-infusion using flow cytometry and quantitative polymerase chain reaction in 13 patients with relapsed refractory diffuse large B-cell lymphoma (DLBCL) treated with tisagenlecleucel (tisa-cel). No relationships were identified between bulk CAR-T kinetics and treatment outcomes. Interestingly, the magnitude of CD4+ CAR-T expansion was higher in responders than in nonresponders, while CD8+ CAR-T expansion was minimal in responders. Additionally, CAR-T proliferation was more pronounced in patients with cytokine release syndrome. Our results suggest that CD4+ CAR-T cellular kinetics within 1 month after CAR-T infusion may predict its efficacy after tisa-cel therapy in adult patients with DLBCL.

• Authors: Ryo Hanajiri, Katsuya Furukawa, Marie Nakashima, Yoko Ushijima, Kazuyuki Shimada, Yuichi Ishikawa, Seitaro Terakura, Makoto Murata, Hitoshi Kiyoi
• Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology (Rinsho Ketsueki) Vol. 64 Issue 3 Pg. 167-174 ( 2023) ISSN: 0485-1439 [Print] Japan
• PMID: 37019669 (Publication Type: English Abstract, Journal Article)

Chemical References

• tisagenlecleucel
• Receptors, Chimeric Antigen
• Receptors, Antigen, T-Cell
• Antigens, CD19

Topics

• Adult
• Humans
• Receptors, Chimeric Antigen (therapeutic use)
• Receptors, Antigen, T-Cell (therapeutic use)
• Lymphoma, Large B-Cell, Diffuse (drug therapy)
• T-Lymphocytes
• Immunotherapy, Adoptive (methods)
• Antigens, CD19 (therapeutic use)